secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cocrystal Pharma, Inc. (COCP)
CIK:        0001412486
Form:       8-K
Filed at:   2026-09-09T12:00:19+00:00
Accession:  0001493152-26-041877
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cocrystal Pharma completes dosing in Phase 1b norovirus challenge study for CDI-988
--------------------------------------------------------------------------------

- Last subject dosed in Phase 1b norovirus challenge study (NCT07198139) evaluating CDI-988 as preventive and treatment.
- No serious adverse events reported to date; CDI-988 previously safe at 1200 mg dose in Phase 1.
- Preliminary efficacy results expected late 2026 or early 2027.
- Study at Emory University enrolled healthy adults 18-49 infected with GII.2 (Snow Mountain Virus) strain.
- CDI-988 is first oral antiviral for norovirus, designed to inhibit replication in all known strains.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1412486/000149315226041877/0001493152-26-041877-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1412486/000149315226041877/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-041877

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer